Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Kenichi Ogiwara, MD PhD, Hiroki Horiuchi, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2018-99-118379

Published: 2018

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

Furukawa Shoko, Keiji Nogami, MD PhD, Kenichi Ogiwara, MD PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1391.

https://doi.org/10.1182/blood.V128.22.1391.1391

Published: 2016

Journal Articles

Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A

Kenichi Ogiwara, MD PhD, Laura L Swystun, PhD, Ilinca Georgescu, Christine Brown, Angie Tuttle, Shawn Tinlin, Jayne Leggo, Silvia Albánez, MSc, Manuel Carcao, MD MSc, Victor S. Blanchette, MD FRCPC, Christoph Male, MD MSC, Katharina Thom, David Lillicrap, MD

Blood (2014) 124 (21): 473.

https://doi.org/10.1182/blood.V124.21.473.473

Published: 2014

Journal Articles

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Junka Haku, MD, Kenichi Ogiwara, MD, PhD, Tomoko Matsumoto, PhD, Koji Yada, MD, Midori Shima, MD, PhD, Keiji Nogami, MD, PhD

Blood (2012) 120 (21): 3382.

https://doi.org/10.1182/blood.V120.21.3382.3382

Published: 2012

Journal Articles

A Coagulation Mechanism for the Mild Bleeding Tendency in a Patient with Severe Hemophilia A Possessing an Arg1781His Mutation.

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Hironao Wakabayashi, MD, PhD, Philip J. Fay, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2213.

https://doi.org/10.1182/blood.V120.21.2213.2213

Published: 2012

Journal Articles

The Characteristics and Mechanism(s) of Anti-Factor VIII Antibody Developed in Mild Hemophilia A Associated with a Novel Mutation Pro1809Leu.

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2215.

https://doi.org/10.1182/blood.V120.21.2215.2215

Published: 2012

Journal Articles

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Tomoko Matsumoto, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2232.

https://doi.org/10.1182/blood.V120.21.2232.2232

Published: 2012

Journal Articles

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease.

Kenichi Ogiwara, MD, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, PhD, Shoko Furukawa, MD, Hiroaki Minami, MD, Kazuya Hosokawa, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2237.

https://doi.org/10.1182/blood.V120.21.2237.2237

Published: 2012

Journal Articles

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Katsumi Nishiya, MD, PhD, Ichiro Tanaka, MD, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Koji Yada, MD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 3320.

https://doi.org/10.1182/blood.V118.21.3320.3320

Published: 2011

Journal Articles

Evaluation of Comprehensive Hemostatic Function of Patients with Von Willebrand Disease (VWD) Under Flow Using a New Microchip Flow Chamber System

Kenichi Ogiwara, MD, PhD, Kazuya Hosokawa, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 2283.

https://doi.org/10.1182/blood.V118.21.2283.2283

Published: 2011

Journal Articles

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

Kenichi Ogiwara, MD, PhD, Keiko Shinozawa, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Koji Yada, MD, Katsuyuki Fukutake, MD, PhD, Midori Shima, MD, PhD

Blood (2011) 118 (21): 537.

https://doi.org/10.1182/blood.V118.21.537.537

Published: 2011

Journal Articles

A novel mechanism of Enhancing the Haemostatic Effect in the Combination with Recombinant Factor VIII and Activated Prothrombin Complex Concentrate(APCC) in Hemophilia A Patients with Inhibitor

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2011) 118 (21): 1178.

https://doi.org/10.1182/blood.V118.21.1178.1178

Published: 2011

Journal Articles

Tissue Factor Pathway Inhibitor Causes Unresponsiveness to Activated Prothrombin Complex Concentrates for Hemophilia A Patients with Inhibitors.

Kenichi Ogiwara, MD, Keiji Nogami, MD, PhD, Ichiro Tanaka, MD, PhD, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 3663.

https://doi.org/10.1182/blood.V116.21.3663.3663

Published: 2010

Journal Articles

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 3666.

https://doi.org/10.1182/blood.V116.21.3666.3666

Published: 2010

Journal Articles

Procoagulant Activity of Antifibrinolytic Agents; A Novel Hemostatic Mechanism of Tranexamic Acid and Epsilon-Aminocaproic Acid.

Kenichi Ogiwara, MD, Keiji Nogami, MD, PhD, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 1151.

https://doi.org/10.1182/blood.V116.21.1151.1151

Published: 2010

Journal Articles

Role of the Direct Interaction between Factor VIII C2 and Factor IXa Gla Domain in the Factor Xase Complex.

Tetsuhiro Soeda, Keiji Nogami, MD, PhD, Masahiro Takeyama, MD, Kenichi Ogiwara, MD, Kazuhiko Tomokiyo, PhD, Yoichi Sakata, MD, PhD, Akira Yoshioka, MD, PhD, Midori Shima, MD, PhD

Blood (2007) 110 (11): 2687.

https://doi.org/10.1182/blood.V110.11.2687.2687

Published: 2007

NARROW

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

A Coagulation Mechanism for the Mild Bleeding Tendency in a Patient with Severe Hemophilia A Possessing an Arg1781His Mutation.

The Characteristics and Mechanism(s) of Anti-Factor VIII Antibody Developed in Mild Hemophilia A Associated with a Novel Mutation Pro1809Leu.

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease.

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Evaluation of Comprehensive Hemostatic Function of Patients with Von Willebrand Disease (VWD) Under Flow Using a New Microchip Flow Chamber System

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

A novel mechanism of Enhancing the Haemostatic Effect in the Combination with Recombinant Factor VIII and Activated Prothrombin Complex Concentrate(APCC) in Hemophilia A Patients with Inhibitor

Tissue Factor Pathway Inhibitor Causes Unresponsiveness to Activated Prothrombin Complex Concentrates for Hemophilia A Patients with Inhibitors.

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Procoagulant Activity of Antifibrinolytic Agents; A Novel Hemostatic Mechanism of Tranexamic Acid and Epsilon-Aminocaproic Acid.

Role of the Direct Interaction between Factor VIII C2 and Factor IXa Gla Domain in the Factor Xase Complex.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only